{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:20:23Z","timestamp":1760782823577},"reference-count":33,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[1992,2,1]],"date-time":"1992-02-01T00:00:00Z","timestamp":696902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[1992,2]]},"DOI":"10.1016\/s0959-8049(05)80077-2","type":"journal-article","created":{"date-parts":[[2005,12,2]],"date-time":"2005-12-02T12:29:15Z","timestamp":1133526555000},"page":"463-469","source":"Crossref","is-referenced-by-count":15,"title":["Phase I trial of the anthrapyrazole CI-941: Prospective evaluation of a pharmacokinetically guided dose-escalation"],"prefix":"10.1016","volume":"28","author":[{"given":"B.J.","family":"Foster","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.R.","family":"Newell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.A.","family":"Gumbrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.H.","family":"Calvert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.B.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.E.","family":"Jenns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S0959-8049(05)80077-2_bib1","first-page":"65","article-title":"Relation of preclinical toxicology to findings in early clinical trials","volume":"70","author":"Grieshaber","year":"1986","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/S0959-8049(05)80077-2_bib2","first-page":"51","article-title":"Anticancer drugs: phase I trials","volume":"6","author":"Calvert","year":"1987","journal-title":"Cancer Topics"},{"key":"10.1016\/S0959-8049(05)80077-2_bib3","first-page":"73","article-title":"Potential roles for preclinical pharmacology in phase I clinical trials","volume":"70","author":"Collins","year":"1986","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/S0959-8049(05)80077-2_bib4","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/0277-5379(87)90365-8","article-title":"Commentary and proposed guidelines on \u201cpharmacokinetically-guided dose escalation in phase I clinical trials\u201d","volume":"23","year":"1987","journal-title":"Eur J Clin Oncol"},{"key":"10.1016\/S0959-8049(05)80077-2_bib5","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1016\/0006-2952(85)90724-5","article-title":"In vitro DNA strand scission and inhibition of nucleic acid synthesis in L1210 leukemic cells by a new class of DNA complexes, the anthra[1, 9-cd] pyrazole-6-(2H)-ones (anthrapyrazoles)","volume":"34","author":"Fry","year":"1985","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/S0959-8049(05)80077-2_bib6","first-page":"5532","article-title":"Anthrapyrazoles, a new class of intercalating agents with high level, broad spectrum activity against murine tumors","volume":"45","author":"Leopold","year":"1985","journal-title":"Cancer Res"},{"key":"10.1016\/S0959-8049(05)80077-2_bib7","first-page":"302","article-title":"Cardiotoxic potential of substituted anthra(1,9-cd)pyrazole-6-(2H) ones (anthrapyrazoles) as assessed by the fetal mouse heart organ culture","volume":"25","author":"Fagan","year":"1984"},{"key":"10.1016\/S0959-8049(05)80077-2_bib8","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1016\/0006-2952(87)90309-1","article-title":"The effect of the anthrapyrazole antitumour agent CI-941 on rat liver microsome and cytochrome P450 reductase mediated free radical processes; inhibition of doxorubicin activation in vitro","volume":"36","author":"Graham","year":"1987","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/S0959-8049(05)80077-2_bib9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/BF00258450","article-title":"The pharmacokinetics and toxicity of the anthrapyrazole anticancer drug CI-941 in the mouse: a guide for rational dose escalation in patients","volume":"23","author":"Graham","year":"1989","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/S0959-8049(05)80077-2_bib10","series-title":"WHO Handbook for Reporting Results of Cancer Treatment: World Health Organization","first-page":"48","year":"1979"},{"key":"10.1016\/S0959-8049(05)80077-2_bib11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0378-4347(00)82841-8","article-title":"Determination of the anthrapyrazole anticancer drug CI-941 in plasma and urine by solid phase extraction and high performance liquid chromatography","volume":"491","author":"Graham","year":"1989","journal-title":"J Chromatogr Biomed Appl"},{"key":"10.1016\/S0959-8049(05)80077-2_bib12","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2307\/1266224","article-title":"Application of stepwise regression to non-linear least squares estimation","volume":"10","author":"Jennrich","year":"1968","journal-title":"Technometrics"},{"key":"10.1016\/S0959-8049(05)80077-2_bib13","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1042\/bj1340729","article-title":"Normalization in the fitting of data by iterative methods","volume":"134","author":"Ottaway","year":"1973","journal-title":"Biochem J"},{"key":"10.1016\/S0959-8049(05)80077-2_bib14","series-title":"Fundamentals of Clinical Pharmacokinetics","author":"Wagner","year":"1975"},{"key":"10.1016\/S0959-8049(05)80077-2_bib15","first-page":"219","article-title":"Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man","volume":"50","author":"Freireich","year":"1966","journal-title":"Cancer Chemotherapy Rep"},{"key":"10.1016\/S0959-8049(05)80077-2_bib16","first-page":"1354","article-title":"Quantitative prediction of drug toxicity in humans from toxicology in small and large animals","volume":"35","author":"Goldsmith","year":"1975","journal-title":"Cancer Res"},{"key":"10.1016\/S0959-8049(05)80077-2_bib17","first-page":"2204","article-title":"Adequacies and inadequacies in assessing murine toxicity data with antineoplastic agents","volume":"39","author":"Guarino","year":"1979","journal-title":"Cancer Res"},{"key":"10.1016\/S0959-8049(05)80077-2_bib18","first-page":"21","article-title":"Animal toxicology for early clinical trials with anticancer agents","volume":"4","author":"Rozencweig","year":"1981","journal-title":"Cancer Clin Trials"},{"key":"10.1016\/S0959-8049(05)80077-2_bib19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1021\/jm00384a021","article-title":"Anthrapyrazole anticancer agents. Synthesis and structure\u2014activity relationships against murine leukemias","volume":"30","author":"Showalter","year":"1987","journal-title":"J Med Chem"},{"key":"10.1016\/S0959-8049(05)80077-2_bib20","series-title":"New Avenues in Developmental Cancer Chemotherapy","first-page":"355","article-title":"5-aminoanthrapyrazoles (CI-937, CI-941, CI-942): a novel class of DNA binders with broad-spectrum anticancer activity","author":"Werbel","year":"1987"},{"key":"10.1016\/S0959-8049(05)80077-2_bib21","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0021-9681(62)90003-6","article-title":"Predicting anticancer drug effects in man from laboratory animal studies","volume":"15","author":"Owens","year":"1963","journal-title":"J Chronic Dis"},{"key":"10.1016\/S0959-8049(05)80077-2_bib22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/cpt19701113","article-title":"The evaluation of anticancer drugs in man","volume":"14","author":"Schein","year":"1970","journal-title":"Clin Pharm Ther"},{"key":"10.1016\/S0959-8049(05)80077-2_bib23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1056\/NEJM198107163050305","article-title":"The anthracycline antineoplastic drugs","volume":"305","author":"Young","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1016\/S0959-8049(05)80077-2_bib24","doi-asserted-by":"crossref","first-page":"67","DOI":"10.7326\/0003-4819-105-1-67","article-title":"Mitoxantrone: a new anticancer drug with significant clinical activity","volume":"105","author":"Shenkenberg","year":"1986","journal-title":"Annals Int Med"},{"key":"10.1016\/S0959-8049(05)80077-2_bib25","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0959-8049(05)80077-2_bib26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF00684957","article-title":"Phase I study of the anthrapyrazole biantrazole: clinical results and pharmacology","volume":"28","author":"Allan","year":"1991","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/S0959-8049(05)80077-2_bib27","first-page":"299","article-title":"Time course study on doxorubicin-induced nephropathy and cardiomyopathy in male and female LOU\/M\/WSL rats: lack of evidence for a causal relationship","volume":"76","author":"Van Hoesel","year":"1986","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/S0959-8049(05)80077-2_bib28","series-title":"Toxicity of Chemotherapy","first-page":"317","article-title":"Renal and metabolic toxicities of cancer treatment","author":"Schilsky","year":"1984"},{"key":"10.1016\/S0959-8049(05)80077-2_bib29","series-title":"4th International Nephrotoxicity Symposium","article-title":"Marked nephrotoxicity associated with the anthrapyrazole anticancer drug CI-941","author":"Camplings","year":"1989"},{"key":"10.1016\/S0959-8049(05)80077-2_bib30","first-page":"3905","article-title":"Phase I clinical and pharmacological evaluation of pirozantrone hydrochloride (oxantrazole)","volume":"50","author":"Ames","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/S0959-8049(05)80077-2_bib31","first-page":"3284","article-title":"Phase I study and pharmacokinetics of piroxantrone (NSC 349174), a new anthrapyrazole","volume":"50","author":"Hantel","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/S0959-8049(05)80077-2_bib32","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/jnci\/82.6.469","article-title":"Pharmacology and clinical toxicity of 4\u2032-iodo-4\u2032-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials","volume":"82","author":"Gianni","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/S0959-8049(05)80077-2_bib33","first-page":"84","article-title":"Phase II study of anthrapyrazole CI-941. A highly active drug against advanced breast cancer","volume":"9","author":"Mansi","year":"1990"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804905800772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804905800772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,20]],"date-time":"2019-01-20T14:00:37Z","timestamp":1547992837000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804905800772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,2]]},"references-count":33,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[1992,2]]}},"alternative-id":["S0959804905800772"],"URL":"https:\/\/doi.org\/10.1016\/s0959-8049(05)80077-2","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[1992,2]]}}}